118 related articles for article (PubMed ID: 20883151)
1. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims.
Chastek BJ; Oleen-Burkey M; Lopez-Bresnahan MV
J Med Econ; 2010; 13(4):618-25. PubMed ID: 20883151
[TBL] [Abstract][Full Text] [Related]
2. Identifying Patients With Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Healthcare Data.
Van Le H; Le Truong CT; Kamauu AWC; Holmén J; Fillmore C; Kobayashi MG; Martin C; Sabidó M; Wong SL
Value Health; 2019 Jan; 22(1):77-84. PubMed ID: 30661637
[TBL] [Abstract][Full Text] [Related]
3. Development of an algorithm to identify preoperative medical consultations using administrative data.
Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Buckley DN; Laupacis A
Med Care; 2009 Dec; 47(12):1258-64. PubMed ID: 19890221
[TBL] [Abstract][Full Text] [Related]
4. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Multiple Sclerosis Neuropsychological Screening Questionnaire in Argentina.
Vanotti S; Benedict RH; Acion L; Cáceres F;
Mult Scler; 2009 Feb; 15(2):244-50. PubMed ID: 18845653
[TBL] [Abstract][Full Text] [Related]
6. Brain excitability changes in the relapsing and remitting phases of multiple sclerosis: a study with transcranial magnetic stimulation.
Caramia MD; Palmieri MG; Desiato MT; Boffa L; Galizia P; Rossini PM; Centonze D; Bernardi G
Clin Neurophysiol; 2004 Apr; 115(4):956-65. PubMed ID: 15003779
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study.
Quigley HA; Friedman DS; Hahn SR
Ophthalmology; 2007 Sep; 114(9):1599-606. PubMed ID: 17572498
[TBL] [Abstract][Full Text] [Related]
8. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2007 Sep; 69(12):1230-5. PubMed ID: 17875911
[TBL] [Abstract][Full Text] [Related]
9. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
10. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study.
Salemi G; Callari G; Gammino M; Battaglieri F; Cammarata E; Cuccia G; D'Amelio M; Lupo I; Ragonese P; Savettieri G
Acta Neurol Scand; 2004 Jul; 110(1):23-6. PubMed ID: 15180803
[TBL] [Abstract][Full Text] [Related]
11. Effect of a retrospective drug utilization review on potentially inappropriate prescribing in the elderly.
Starner CI; Norman SA; Reynolds RG; Gleason PP
Am J Geriatr Pharmacother; 2009 Feb; 7(1):11-9. PubMed ID: 19281936
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
13. Specificity of frontal dysfunctions in relapsing-remitting multiple sclerosis.
Santiago O; Guàrdia J; Casado V; Carmona O; Arbizu T
Arch Clin Neuropsychol; 2007 Jun; 22(5):623-9. PubMed ID: 17482795
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
15. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of sTNFR-1 and sFas in patients with relapsing-remitting multiple sclerosis.
Bilińska M; Frydecka I; Podemski R; Gruszka E
Med Sci Monit; 2002 Oct; 8(10):CR720-3. PubMed ID: 12388926
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
[TBL] [Abstract][Full Text] [Related]
18. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
19. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
[TBL] [Abstract][Full Text] [Related]
20. Clinical parameters and HHV-6 active replication in relapsing-remitting multiple sclerosis patients.
Alvarez-Lafuente R; García-Montojo M; De las Heras V; Bartolomé M; Arroyo R
J Clin Virol; 2006 Dec; 37 Suppl 1():S24-6. PubMed ID: 17276363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
